Ameriprise Financial Inc. Has $268.06 Million Position in The Cooper Companies, Inc. (NASDAQ:COO)

Ameriprise Financial Inc. lessened its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 3.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,915,953 shares of the medical device company's stock after selling 90,715 shares during the quarter. Ameriprise Financial Inc. owned approximately 1.46% of Cooper Companies worth $268,064,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in COO. Byrne Asset Management LLC purchased a new stake in shares of Cooper Companies during the fourth quarter worth approximately $33,000. OFI Invest Asset Management purchased a new stake in Cooper Companies in the fourth quarter valued at approximately $34,000. New Age Alpha Advisors LLC acquired a new stake in Cooper Companies during the 4th quarter worth approximately $38,000. Covestor Ltd boosted its position in Cooper Companies by 35.5% in the 4th quarter. Covestor Ltd now owns 458 shares of the medical device company's stock valued at $42,000 after buying an additional 120 shares during the period. Finally, West Financial Advisors LLC acquired a new position in shares of Cooper Companies in the fourth quarter worth $49,000. 24.39% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on COO. BNP Paribas upgraded Cooper Companies to a "hold" rating in a report on Thursday, March 13th. Robert W. Baird reduced their price objective on shares of Cooper Companies from $117.00 to $107.00 and set an "outperform" rating on the stock in a report on Friday, March 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Cooper Companies in a report on Friday, March 7th. JPMorgan Chase & Co. decreased their price objective on shares of Cooper Companies from $120.00 to $110.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Finally, Citigroup cut their price target on Cooper Companies from $115.00 to $110.00 and set a "buy" rating on the stock in a research report on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Cooper Companies presently has a consensus rating of "Moderate Buy" and a consensus price target of $110.25.

Cooper Companies Stock Down 0.8 %

Shares of COO traded down $0.65 during mid-day trading on Friday, reaching $82.27. The company's stock had a trading volume of 1,265,544 shares, compared to its average volume of 1,447,855. The business has a fifty day moving average of $80.54 and a 200 day moving average of $90.93. The company has a market cap of $16.45 billion, a price-to-earnings ratio of 42.19, a price-to-earnings-growth ratio of 2.25 and a beta of 1.08. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The Cooper Companies, Inc. has a 1 year low of $69.81 and a 1 year high of $112.38.

Cooper Companies (NASDAQ:COO - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The firm had revenue of $964.70 million for the quarter, compared to the consensus estimate of $981.25 million. As a group, analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.